Population Pharmacokinetics and Exposure‐Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

ABSTRACT Ziftomenib, a potent, highly selective, oral menin inhibitor, has demonstrated significant clinical benefit and deep responses in relapsed and/or refractory (R/R) nucleophosmin 1‐mutated (NPM1‐m) acute myeloid leukemia (AML) patients. Here we present data from analyses conducted to characte...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Amitava Mitra, Xiaoyan Yang, Roberto H. Ortiz, Claudia Jomphe, Mollie Leoni, Nathalie H. Gosselin
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-05-01
Edice:	CPT: Pharmacometrics & Systems Pharmacology
On-line přístup:	https://doi.org/10.1002/psp4.70244
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!